John Bisi
YOU?
Author Swipe
View article: Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Description of methods to synthesize INX-315
View article: Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
LanthaScreen Eu Kinase Binding and Z’-Lyte Kinase Assay data for INX-315
View article: Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Supplementary Figure 1: Characterization of INX-315.Supplementary Figure 2: Effect of INX-315 and PF-07104091 on viability of cancer and non-malignant cell lines.Supplementary Figure 3: Effect of INX-315 on cell cycle in CCNE1-amplified ca…
View article: Supplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Experimental conditions for Nanosyn assays
View article: Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle Open
Cyclin dependent kinase 2 (CDK2) regulates cell cycle and is an emerging target for cancer therapy. There are relatively small numbers of tumor models that exhibit strong dependence on CDK2 and undergo G1 cell cycle arrest following CDK2 i…
View article: Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Activity of INX-315 in CCNE1-amplified cancers. A, IC50s for palbociclib and INX-315 for cell lines shown using CellTiter Glo viability assay. All cells were treated for 6 days, n = 3 technical replicates per cell line. B, Cell cycle phase…
View article: Figure 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Discovery and characterization of INX-315. A, Amino acid sequence homology at the ATP-binding pockets of several CDKs. B, Derivation of INX-315 through serial modifications of trilaciclib, a CDK4/6i. Table indicates biochemical IC50s (± SE…
View article: Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
LanthaScreen Eu Kinase Binding and Z’-Lyte Kinase Assay data for INX-315
View article: Supplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Experimental conditions for Nanosyn assays
View article: Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Table 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
LanthaScreen Eu Kinase Binding and Z’-Lyte Kinase Assay data for INX-315
View article: Figure 4 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 4 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Activity of INX-315 in CDK4/6i–resistant breast cancer. A, Dose–response curves for MCF7 and T47D cell lines treated with INX-315 for 7 days. Parent, parent cells in DMSO; Abema-resistant, abemaciclib-resistant cells growing in 500 nmol/L …
View article: Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Description of methods to synthesize INX-315
View article: Figure 6 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 6 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
INX-315 delays the onset of acquired CDK4/6i resistance. A, Representative images from a clonogenic assay in which MCF7 and T47D cells were treated with control vehicle, abemaciclib (500 nmol/L), INX-315 (300 nmol/L for MCF7, 100 nmol/L fo…
View article: Figure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
INX-315 treatment of CDK4/6i–resistant breast cancer reinstates a senescence phenotype. A, Representative images (top) and quantification (bottom) of staining MCF7 and T47D cells for beta-galactosidase activity after treatment with agents …
View article: Data from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Data from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Cyclin-dependent kinase 2 (CDK2) is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification and breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i…
View article: Supplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Table 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Experimental conditions for Nanosyn assays
View article: Figure 3 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 3 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
TIS after INX-315 treatment of CCNE1-amplified cancers. A, Left, representative images after staining OVCAR3 and MKN1 cells for beta-galactosidase activity after treatment with INX-315 (scale bar = 100 μm). Experiments performed with three…
View article: Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Activity of INX-315 in CCNE1-amplified cancers. A, IC50s for palbociclib and INX-315 for cell lines shown using CellTiter Glo viability assay. All cells were treated for 6 days, n = 3 technical replicates per cell line. B, Cell cycle phase…
View article: Figure 6 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 6 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
INX-315 delays the onset of acquired CDK4/6i resistance. A, Representative images from a clonogenic assay in which MCF7 and T47D cells were treated with control vehicle, abemaciclib (500 nmol/L), INX-315 (300 nmol/L for MCF7, 100 nmol/L fo…
View article: Figure 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 1 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Discovery and characterization of INX-315. A, Amino acid sequence homology at the ATP-binding pockets of several CDKs. B, Derivation of INX-315 through serial modifications of trilaciclib, a CDK4/6i. Table indicates biochemical IC50s (± SE…
View article: Figure 4 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 4 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Activity of INX-315 in CDK4/6i–resistant breast cancer. A, Dose–response curves for MCF7 and T47D cell lines treated with INX-315 for 7 days. Parent, parent cells in DMSO; Abema-resistant, abemaciclib-resistant cells growing in 500 nmol/L …
View article: Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Synthetic Methods from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Description of methods to synthesize INX-315
View article: Figure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 5 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
INX-315 treatment of CDK4/6i–resistant breast cancer reinstates a senescence phenotype. A, Representative images (top) and quantification (bottom) of staining MCF7 and T47D cells for beta-galactosidase activity after treatment with agents …
View article: Figure 3 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Figure 3 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
TIS after INX-315 treatment of CCNE1-amplified cancers. A, Left, representative images after staining OVCAR3 and MKN1 cells for beta-galactosidase activity after treatment with INX-315 (scale bar = 100 µm). Experiments performed with three…
View article: Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Supplementary Figure 1: Characterization of INX-315. Supplementary Figure 2: Effect of INX-315 and PF-07104091 on viability of cancer and non-malignant cell lines. Supplementary Figure 3: Effect of INX-315 on cell cycle in CCNE1-amplified …
View article: Data from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Data from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Cyclin-dependent kinase 2 (CDK2) is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification and breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i…
View article: Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Supplementary Figures 1-14 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Supplementary Figure 1: Characterization of INX-315. Supplementary Figure 2: Effect of INX-315 and PF-07104091 on viability of cancer and non-malignant cell lines. Supplementary Figure 3: Effect of INX-315 on cell cycle in CCNE1-amplified …
View article: INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors Open
Cyclin-dependent kinase 2 (CDK2) is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification and breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i…
View article: Supp Figure 3 from Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
Supp Figure 3 from Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression Open
Combination therapy of G1T28 and topotecan does not cause a DDI effect.